Mold / Toxin Burden
1. Root Cause Overview
Chronic mold illness (also termed Chronic Inflammatory Response Syndrome, CIRS) results from prolonged exposure to water-damaged buildings containing mold, mycotoxins, bacteria, and their inflammatory byproducts. Mycotoxins (aflatoxins, ochratoxin A, trichothecenes, gliotoxin) are potent immunotoxins, nephrotoxins, and neurotoxins. Genetically susceptible individuals (HLA-DR/DQ variants, ~25% of the population) cannot adequately clear these biotoxins, leading to a chronic multi-system inflammatory state that mimics many other conditions.
2. Common Signs & Symptoms
- Fatigue, weakness, post-exertional malaise
- Cognitive impairment: brain fog, memory loss, word-finding difficulty
- Headaches (often positional or weather-related)
- Unusual ice-pick pains, static shocks, tingling
- Shortness of breath, chronic cough, sinus congestion
- Joint pain and morning stiffness
- Night sweats and temperature dysregulation
- Mood disturbances: anxiety, depression, rage
- Abdominal pain, diarrhoea, appetite changes
- Visual disturbances (blurred vision, light sensitivity)
3. Labs to Consider
CBC/CMP, liver/kidney markers, inflammatory markers (hs-CRP, TGF-β1, C4a, MMP-9 when available); mycotoxin testing and environmental evaluation in trained settings.
Choose the lab option based on what you want to assess within this root cause.
MycoToxin Panel
US BioTek
4. Clinical Priorities
Assess for ongoing or past mold exposure, current symptom triggers, building environment concerns, and individual clearance capacity before designing a protocol. If exposure remains active, environmental remediation or removal may be necessary, but additional contributors such as dysbiosis, impaired detoxification, nutrient depletion, and inflammatory activation should also be evaluated. Consider urine mycotoxin testing, binder support when appropriate, and specialist referral for complex or persistent cases.
Where to Start: Top 2 Supplements
The most accessible and effective mycotoxin binder available without a prescription. Adsorbs multiple mycotoxin classes in the GI tract, preventing systemic absorption and enterohepatic recirculation. Must be taken 2+ hours away from all medications. Start here while awaiting cholestyramine.
Mycotoxins directly deplete glutathione. Liposomal glutathione replenishes the master detoxification molecule, supports Phase II mycotoxin conjugation, and modulates the inflammatory cascade driven by biotoxin exposure. Liposomal form bypasses GI degradation.
5. Diet Strategy
Adopt a low-amylose diet (reduces mold food sources in the gut): eliminate grains, legumes, and high-sugar foods initially. Emphasise clean proteins, non-starchy vegetables, and healthy fats. Avoid foods with high mold content: peanuts, corn, dried fruits, aged cheeses, alcohol. Ensure adequate protein for glutathione synthesis. Hydrate well to support renal mycotoxin excretion. Organic produce reduces additional pesticide burden.
6. Lifestyle Strategy
Environmental assessment and remediation is the primary intervention. Use HEPA air purifiers in living and sleeping spaces. Avoid re-exposure — even brief re-exposure can re-trigger the inflammatory cascade in sensitised individuals. Sauna therapy (infrared preferred) supports mycotoxin excretion through sweat. Manage stress — HPA axis dysregulation is common in mold illness. Gentle exercise (avoid overexertion which worsens symptoms in CIRS).
7. Supplement Strategy
Full supplement list below. See Section 4 (Clinical Priorities) for the recommended Top 2 starting supplements. Add additional supplements based on lab results and clinical response at 4–6 week reassessment.
| Supplement | Dosage | Indication | Evidence | Key Results | Example |
|---|---|---|---|---|---|
| Cholestyramine (prescription binder) [1] Constipation, bloating; binds fat-soluble vitamins and medications — must be taken away from all other agents | 4 g QID (as directed by prescribing physician) | Mycotoxin binding in GI tract; interruption of enterohepatic recirculation | Clinical protocol (Shoemaker CIRS protocol) | Cornerstone of CIRS treatment; binds biotoxins in GI tract preventing reabsorption; reduces inflammatory markers | Prescription only (Questran) |
| Activated Charcoal [2] Constipation; black stools; binds all medications — 2+ hour separation required | 1–2 g BID–TID away from meals and medications | Mycotoxin and chemical toxin binding; GI decontamination | In vitro and clinical evidence | Effective adsorption of multiple mycotoxins (aflatoxin B1, ochratoxin A, zearalenone) in GI tract | Bulletproof Coconut Charcoal |
| Glutathione (Liposomal) [3] Generally well tolerated; start low to avoid detox reactions | 250–500 mg/day | Mycotoxin conjugation and excretion; antioxidant support; immune modulation | Mechanistic and clinical evidence | Supports Phase II detoxification of mycotoxins; replenishes glutathione depleted by mycotoxin exposure | Quicksilver Scientific Liposomal Glutathione |
| NAC (N-Acetyl Cysteine) [4] Nausea at high doses; avoid in active peptic ulcer disease | 600–1,200 mg/day | Glutathione precursor; mycotoxin detoxification support | Animal and clinical studies | Increased hepatic glutathione; protective against ochratoxin A and aflatoxin-induced organ damage | Thorne NAC |
| Curcumin [5] Mild GI upset; avoid in gallstone disease | 500–2,000 mg/day | Hepatoprotection against mycotoxin-induced liver injury; NRF2 activation; anti-inflammatory | Animal study (aflatoxin B1 model) | Prevented decrease in antioxidant enzymes (glutathione peroxidase, catalase); reduced DNA damage and hepatic injury from AFB1 | Nutricology CurcuWIN 500 |
| Saccharomyces boulardii [6] Avoid in immunocompromised patients; generally well tolerated | 5–10 billion CFU/day | Mycotoxin binding in GI tract; gut microbiome protection during mold illness | Animal and in vitro studies | Binds mycotoxins in GI tract; protects gut epithelium from mycotoxin-induced damage | Jarrow Formulas Saccharomyces Boulardii + MOS |
8. Safety Notes
CIRS is a complex multi-system illness requiring specialist management — do not attempt to treat with supplements alone. Environmental remediation is mandatory. Cholestyramine is a prescription medication requiring physician oversight. Aggressive binder therapy can cause severe constipation and nutrient depletion — always support with adequate hydration and fat-soluble vitamin monitoring. Refer to a CIRS-trained practitioner (Shoemaker protocol) for confirmed cases.
9. Citations & References
- [1]Cholestyramine (prescription binder)Shoemaker RC, House DE. Sick building syndrome (SBS) and exposure to water-damaged buildings: time series study, clinical trial and mechanisms. Neurotoxicol Teratol. 2006;28(5):573–588.View source
- [2]Activated CharcoalHuwig A, Freimund S, Käppeli O, Dutler H. Mycotoxin detoxication of animal feed by different adsorbents. Toxicol Lett. 2001;122(2):179–188.View source
- [3]
- [4]NAC (N-Acetyl Cysteine)Sorrenti V, Randazzo CL, Caggia C, et al. Beneficial effects of polyphenols and mycotoxin binding agents in counteracting ochratoxin A toxicity in vitro. Front Microbiol. 2019;10:2680.View source
- [5]CurcuminZhang NY, Qi M, Zhao L, et al. Curcumin prevents aflatoxin B₁ hepatotoxicity by inhibition of cytochrome P450 isozymes in chick liver. Toxins. 2016;8(11):327.View source
- [6]Saccharomyces boulardiiBhaskara Rao MV, Chopra RC. Saccharomyces cerevisiae as a biological detoxifier of aflatoxin in poultry feed. Anim Feed Sci Technol. 2001;93(1–2):95–107.View source
Ask AI About This Protocol
Related Mini-Training
12:18Functional Gastroenterology Quick Start
9:47SIBO: Causes, Testing & Treatment
10:15Anti-Inflammatory Nutrition